Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1487338 | 1.00 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| Hydrochloric Acid SCHEMBL19809927 | 1.00 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| Hydrochloric Acid SCHEMBL21192546 | 0.98 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| SCHEMBL3863416 | 0.98 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| SCHEMBL3863419 | 0.98 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| SCHEMBL22462283 | 0.96 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| SCHEMBL5349175 | 0.86 | SMN1; SMN2 (0.36) | NPC1RAB9ASMN1; SMN2PDK1PDK2 | |
| Hydrochloric Acid SCHEMBL3893006 | 0.84 | MAPT (0.42) | NPC1RAB9AALDH1A1TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL235512 | 0.84 | MAPT (0.42) | NPC1RAB9AALDH1A1TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL3925322 | 0.82 | MAPT (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110498912-B | Curable unsaturated crystalline polyester powder and process for preparing the same | 施乐公司 | 2023-09-01 | — | — | CN | claimed |
| EP-3569634-B1 | CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME | XEROX CORP (US) | 2023-04-19 | — | — | EP | claimed |
| US-10703859-B2 | Compositions comprising unsaturated crystalline polyester for 3D printing | XEROX CORPORATION (US) | 2020-07-07 | — | — | US | claimed |
| US-10655025-B2 | Curable unsaturated crystalline polyester powder and methods of making the same | XEROX CORPORATION (US) | 2020-05-19 | — | — | US | claimed |
| US-20190352521-A1 | CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME | Genesee Valley Innovations, LLC | 2019-11-21 | — | — | US | claimed |
| US-20190352455-A1 | COMPOSITIONS COMPRISING UNSATURATED CRYSTALLINE POLYESTER FOR 3D PRINTING | Genesee Valley Innovations, LLC | 2019-11-21 | — | — | US | claimed |
| EP-3569634-A1 | CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME | Xerox Corporation (US) | 2019-11-20 | — | — | EP | claimed |
| EP-3569633-A1 | COMPOSITIONS COMPRISING UNSATURATED CRYSTALLINE POLYESTER FOR 3D PRINTING | Xerox Corporation (US) | 2019-11-20 | — | — | EP | claimed |
| US-20070298336-A1 | Carrier coating | XEROX CORPORATION (US) | 2007-12-27 | — | — | US | claimed |
| EP-0767212-B1 | PROCESS FOR PRODUCING AN AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER AND AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER | NOF CORP (JP) | 2001-07-18 | — | — | EP | claimed |
| US-6204324-B1 | AN ETHYLENICALLY UNSATURATED POLYMERIZABLE MONOMER HAVING THE PHOSPHORYLCHOLINE GROUP IS POLYMERIZED IN THE PRESENCE OF A NON-METAL POLYMERIZATION INITIATOR SOLUTION CONTAINING PEROXY OR AZO COMPOUNDS | NOF CORPORATION (JP) | 2001-03-20 | — | — | US | claimed |
| US-6136490-A | SUSPENSION POLYMERIZING A MONOMER OR A MIXTURE OF TWO OR MOREMONOMERS FOR A CORE AND SUSPENSION POLYMERIZING A MONOMER OR MIXTURE OR TWO OR MORE MONOMERS FOR SHELL IN DISPERSION MEDIA USING A DIAZO COMPOUND AS POLYMERIZATION INITIATOR | NIPPON ZEON CO., LTD. (JP) | 2000-10-24 | — | — | US | claimed |
| EP-0767212-A1 | PROCESS FOR PRODUCING AN AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER AND AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER | Japan Science and Technology Corporation (JP) | 1997-04-09 | — | — | EP | claimed |
| US-12583999-B2 | Water-absorbing resin particles, absorbing body, and absorbent article | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-12577432-B2 | Organosilicon compound, production method therefor, and curable composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4282653-B1 | ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION | SHINETSU CHEMICAL CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-5260354-A | Additives for electrodepositable coating compositions | PPG INDUSTRIES, INC. (US) | 1993-11-09 | — | — | US | disclosed |
| WO-1993018099-A1 | ADDITIVES FOR ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG INDUSTRIES, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1992017517-A1 | UREA-ALDEHYDE CONDENSATES AND MELAMINE DERIVATIVES COMPRISING FLUOROCHEMICAL OLIGOMERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992017635-A1 | ISOCYANATE DERIVATIVES COMPRISING FLUOROCHEMICAL OLIGOMERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583999-B2 | Water-absorbing resin particles, absorbing body, and absorbent article | AQP1, AQP3, ARID2 | GAA 3684/4885NPC1 2660/4885RAB9A 3737/4885 |
| US-12577432-B2 | Organosilicon compound, production method therefor, and curable composition | ASH2L, DOT1L, DNMT3L | GAA 1531/4885NPC1 364/4885RAB9A 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.